MET and breast cancer: developed mRNA electroporation-generated second generation c-Met-redirected CAR-Ts and demonstrated the antitumor activity of these cells in in vitro killing assays against BT20 (a TNBC-derived breast cancer cell line) and TB129, both with similar c-Met expression levels (189).